Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRASPA in Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00723346Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jan 2006
- Primary completion
- Aug 2008
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by PHAXIAM Therapeutics. Started Jan 2006; status: completed.
02
Drugs
eryaspase
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00723346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723346.